Sermorelin (GHRH 1-29)

Evidence Anchor

BioHarmony 5.9/10

Sermorelin earns its Neutral score by being the most credentialed peptide in a thinly-proven class, not by having strong adult outcome data. If you are an older adult with documented low IGF-1 or age-related somatopause, you want the GHRH peptide with the most regulatory pedigree, and you accept that the modern adult evidence is mixed, it is a reasonable, low-drama experiment, especially stacked with a GHRP. If you expect proven fat loss or guaranteed better sleep, the data is not there, and the better-supported path is tesamorelin. The two biggest real-world frictions are grey-market sourcing quality and the fact that benefits fade the moment you stop. The fairest way to think about it: sermorelin is the safest-feeling, best-documented way to gently nudge your own growth-hormone output, but the proof that nudging it helps a healthy aging adult is still missing. That is exactly what a Neutral score means. It is not a mistake to try and not a slam dunk to recommend. Judge it on your own response over a few weeks of consistent, fasted, pre-sleep dosing, track your IGF-1 and fasting glucose, and stop without ceremony if nothing moves. ✅ Best for: Older adults with low baseline growth-hormone output or documented low IGF-1, the group that responded most clearly to GHRH 1-29, per Corpas 1992. Men in particular, since the one positive adult lean-mass result was male-only, per Khorram 1997. People who want the gentlest, most credentialed entry point into growth-hormone peptides and will judge it on their own response over a few weeks. Anyone who can verify pharmaceutical-grade compounded material with a certificate of analysis. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on rather than a foundation. ❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can drive proliferation, an absolute contraindication. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin and fasting glucose can rise, per Kirk 1994. You compete in tested sport, since growth-hormone-releasing factors are banned at all times under WADA category S2. You cannot verify your source, because compounded and research-chemical sermorelin vary in purity and dose, and that quality gap can exceed the intrinsic risk of the molecule.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.